A recent report claims that the pharmaceutical and diagnostic company, Rosetta Genomics, has agreed a licence and collaboration agreement with Prometheus Laboratories granting the firm rights to three microRNA-based cancer diagnostic tests in the United States.

Prometheus is to make an equity investment of around eight million dollars to Rosetta Genomics at four dollars per ordinary share. The agreement also includes milestone payments to Rosetta Genomics, funding for research, and royalties in net sales in the United States.

Joseph M. Limber, President and Chief Executive Officer of Prometheus, said: “We believe these three molecular diagnostic tests can help oncologists personalize therapy and are ideally suited to lead our entry into the oncology market, while complementing our emerging internal oncology diagnostics program.”

Amir Avniel, President and Chief Executive Officer of Rosetta Genomics, said: “We are delighted to enter into this comprehensive partnership with Prometheus. With Prometheus these tests now will be available across the U.S., and will be supported by an organization with a proven ability in diagnostic testing services and in launching new products.”

Be Sociable, Share!